CGAS and prostate carcinoma: By trapping PARP on damaged chromatin and augmenting unresolved DNA lesions, PARP inhibitors promote the generation of micronuclei and cytoplasmic DNA in prostate cancer and instigate activation of the cGAS–STING pathway.